United States Federal Circuit

In a patent infringement suit, related to 1-biphenylmethylimidazole compounds and their use as angiotensin receptor blockers (ARBs) for the treatment of high blood pressure, district court's decision sustaining the validity of a patent under 35 U.S.C. section 103 is affirmed as the district court did not err in holding that defendant failed to establish a prima facie case of obviousness because defendant failed to show that one of ordinary skill in the art would have been motivated to select the '902 ARBs as lead compounds or, even if they had, that the skilled artisan would have been motivated to modify the '902 compounds to synthesize the claimed invention.

Appellate Information

• Decided 09/09/2010
• Published 09/09/2010

Judges

• LOURIE

Court

• United States Federal Circuit

Counsel

• For Appellant:
  
• Dominick A. Conde, Robert L. Byer